Bacteria have evolved ways to evade the use of antimicrobials,   leading to the rise of multidrug-resistant  bacteria. This is   particularly true in the case of Gram-Negative  bacteria such     as Acinetobacter baumannii, Klebsiella pneumoniae, E.coli  

  and Pseudomonas aeruginosa.                          


  Given the high unmet medical need and the dwindling number     of effective antibiotics, Bioharmony Therapeutics is       developing a pipeline of lysins for infections caused by     multidrug-resistant Gram-Negative bacteria.